Tyrosine kinase inhibitors in treatment of fibrous histiocytoma

• Veröffentlicht in: Experimental Oncology
• Datum: 2009
• ISSN: 1812-9269
• Hauptverfasser: Maur, D., Panou, C., Valachis, A., Kamposioras, K., Tsali, L.
• Format: Artikel
• Sprache: Englisch
• Veröffentlicht: Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України 2009
• Schlagworte: Short communications
• Online Zugang: https://nasplib.isofts.kiev.ua/handle/123456789/135111
• Назва журналу: Digital Library of Periodicals of National Academy of Sciences of Ukraine
• Zitieren: Tyrosine kinase inhibitors in treatment of fibrous histiocytoma / D. Mauri, C. Panou, A. Valachis, K. Kamposioras, L. Tsali // Experimental Oncology. — 2009. — Т. 31, № 1. — С. 60-61. — Бібліогр.: 18 назв. — англ.

Aim: To describe potential beneficial effects of tyrosine kinase inhibitor in the treatment of unresectable/metastatic fibrous histiocytoma.
 Methods: We report a case of advanced stage fibrous histiocytoma with locally recurrent disease plus lung and bone
 metastatic deposits. Patient was treated with the tyrosine kinase inhibitor sunitinib. Results: Treatment with Sunitinib resulted in
 disease stabilization in the regional lesion and in good partial response for metastatic foci (reduction in number and size). After
 13 months of treatment the patient is doing well with no tumor progression. Conclusions: This case appears to be one of the first
 documentations of beneficial effect and potential long-term benefit of TKIs in the treatment of fibrous histiocytoma.